Ingen Hires Firm to Complete GSA Contract for Government Buying

YUCAIPA, Calif., July 14, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc.
(Pink Sheets:IGNT), a leading Global Medical Device manufacturer focused in the
$4 Billion U.S. Respiratory Market for the growing aging and emerging markets
for Home (DME), Hospital and Aviation Industries, announced today that they have
hired KGMA Business Solutions to complete the GSA filing requirements.

The Texas based KGMA was hired to complete the General Services Administration
(GSA) and E-Buy filings for Ingen. KGMA maintains relationships with thousands
of contracting and small business specialists within the Federal Government and
Fortune 500 markets. KGMA will assist Ingen to identify, develop and deliver
high-performance businesses to provide cost-effective solutions for Fortune 500
and Government agencies.

GSA serves as the acquisition and procurement arm of the federal government,
offering equipment, supplies, telecommunications, and integrated information
technology solutions to federal agencies so that the agencies can focus on
providing products and services. As the federal government's purchasing agent,
GSA connects federal purchasers with the most cost-effective and high-quality
commercial products and services.

At any level of government, public purchasers search for good buys. By comparing
prices, product quality, delivery terms, added services, and other determining
factors, purchasers can be assured that they're spending taxpayer dollars
wisely. To help state and local agencies enjoy cost savings and streamlined
procedures for procuring medical technology, the U.S. Congress passed
legislation to allow cooperative purchasing from federal contracts. The new
Oxyview Nasal Cannula would be a very competitive product in the VA Hospitals,
VA patients needing home oxygen therapy, and military medical units. The Oxyview
Nasal Cannula is priced at $5.75.

"I have enjoyed working with Kenneth Kurk, the CEO of KGMA Business Solutions
and I look forward to completing the GSA filing in a swift and efficient manner.
We have recently received inquiries from the United States Navy regarding the
purchase of our Oxyview products," Stated Scott R. Sand, Chief Executive Officer
of Ingen Technologies.

Ingen submitted for GSA in 2007, and was required to meet a specific sales quota
before being approved. The company has recently reached the sales quota and
expects approval once KGMA has prepared and filed the revised GSA documents.

http://www.kgmasolutions.com/management.html

http://www.gsa.gov/Portal/gsa/ep/home.do?tabId=0

About Ingen Technologies/Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical
product line for the respiratory market worth an estimated $4 Billion in the US,
and $8 billion globally. The company introduced Oxyview into the respiratory
market in late 2007 after securing US and Foreign Patents and successful
licensing with the Food & Drug Administration, and has commenced domestic and
global distribution with manufacture representative organizations, and OEM
partners. In addition to selling its respiratory products within the global
medical industry, the company is selling the same products within other
industries that include aviation, automotive, emergency response, military and
government transportation. The company holds a Device Manufacturing License with
the State of California, Department of Public Health, Food and Drug Branch as it
manufacturers all of its respiratory products in the United States. There are 32
million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600
million patients worldwide. Ingen Technologies is now the largest manufacturer
of in-line gravity-independent oxygen flow meters.

www.ingen-tech.com

The Ingen Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements:

This news release includes forward-looking statements. While these statements
are made to convey to the public the company's progress, business opportunities
and growth prospects, readers are cautioned that such forward-looking statements
represent management's opinion. Whereas management believes such representations
to be true and accurate based on information and data available to the company
at this time, actual results may differ materially from those described. The
company's operations and business prospects are always subject to risk and
uncertainties. Important factors that may cause actual results to differ are and
will be set forth in the company's periodic filings with the U.S. Securities and
Exchange Commission.

-0-
CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
www.INGEN-TECH.COM